Wyeth ReFacto promotion cited by FDA
Executive Summary
Wyeth discontinues ReFacto promotional brochure after FDA cites unsubstantiated safety claims. ReFacto material claimed "albumin-free final formulation for unsurpassed viral safety," FDA's Feb. 2 1letter says. "FDA is unaware of any data supporting the claim." Low ReFacto demand is causing Wyeth to close St. Louis manufacturing facility (2"The Pink Sheet" Jan. 26, 2004, p. 36)...
You may also be interested in...
Wyeth Closes ReFacto And Premarin Facilities, Cites Low Demand As Reason
Wyeth is closing its ReFacto manufacturing plant in St. Louis due to lower demand for the antihemophilic Factor VIII product
IGI Bets On Trispecific Antibody To Make Inroads Into Big Pharma Myeloma Turf
Ichnos Glenmark Innovation’s president and CEO talks to Scrip about the promising activity profile of the alliance’s early stage trispecific antibody versus Janssen’s teclistamab and also maintains that the setback for Gilead’s magrolimab hasn’t eclipsed prospects for its bispecific antibody.
UK Medtech Strategy Sets Out Schedule Of Milestones To FY 2026
Fourteen months on from the release of its inaugural medtech strategy, the UK MedTech Directorate has laid firm foundations and reports progress on initiatives aimed at improving technology adoption. A schedule of ambitious future timelines has also been published.